STOCK MARKET BSE NSE

Single dose of Sputnik V Covid vaccine triggers strong antibody response: Study

The high antibody levels after a single Sputnik V dose in naive participants suggest a benefit of delaying second dose administration to increase the number of people vaccinated.

Published: 14th July 2021 01:37 PM  |   Last Updated: 14th July 2021 01:38 PM   |  A+A-

Previous studies have found that two doses of Sputnik V results in 92 per cent efficacy against COVID-19 infection. (Image for representational purposes only.)

Previous studies have found that two doses of Sputnik V results in 92 per cent efficacy against COVID-19 infection. (Image for representational purposes only.)

By PTI

LONDON: A single dose of the Sputnik V vaccine may be enough to elicit a strong antibody response against SARS-CoV-2, the virus that causes COVID-19, in already infected people, according to a study.

Previous studies have found that two doses of Sputnik V, a vector vaccine produced using a combination of two adenoviruses, results in 92 per cent efficacy against COVID-19 infection.

Adenoviruses are common viruses that cause a range of illnesses with cold-like symptoms such as fever and sore throat.

The new study, published on Tuesday, July 13, 2021, in the journal Cell Reports Medicine, examined whether a single dose would achieve greater public health benefit than two doses by allowing the protection of a larger population more quickly.

ALSO READ: Serum Institute to start manufacturing Sputnik vaccine in September

"Due to limited vaccine supply and uneven vaccine distribution in many regions of the world, health authorities urgently need data on the immune response to vaccines to optimize vaccination strategies," said study senior author Andrea Gamarnik of the Fundacion Instituto Leloir-CONICET in Buenos Aires, Argentina.

"The peer-reviewed data we present provide information for guiding public health decisions in light of the current global health emergency," Gamarnik said.

The researchers noted that evidence from other vaccines offers support for the one-shot approach.

The AstraZeneca vaccine, for example, shows 76 per cent efficacy after a single dose, and the Moderna and Pfizer vaccines may induce sufficient immunity in previously infected individuals after one dose, with no apparent benefit of an additional dose, they said.

In the latest study, the researchers compared the effects of one and two shots of Sputnik V on SARS-CoV-2-specific antibody responses in 289 healthcare workers in Argentina.

Three weeks after the second dose, all volunteers with no prior infection generated virus-specific immunoglobulin G (IgG) antibodies -- the most common type of antibody found in blood.

However, even within three weeks of receiving the first dose, 94 per cent of these participants developed IgG antibodies against the virus, and 90 per cent showed evidence of neutralising antibodies, which interfere with the ability of viruses to infect cells.

The research further showed that IgG and neutralising antibody levels in previously infected participants were significantly higher after one dose than those in fully vaccinated volunteers with no history of infection.

A second dose did not increase the production of neutralising antibodies in previously infected volunteers.

"This highlights the robust response to vaccination of previously infected individuals, suggesting that naturally acquired immunity might be enhanced sufficiently by a single dose, in agreement with recent studies using mRNA vaccines," Gamarnik said.

The researchers noted that further studies are needed to evaluate the duration of the immune response and to assess how antibody levels relate to vaccine protection against COVID-19.

The high antibody levels after a single dose in naive participants suggest a benefit of delaying second dose administration to increase the number of people vaccinated, they said.

"Evidence based on quantitative information will guide vaccine deployment strategies in the face of worldwide vaccine supply restriction," Gamarnik added.
 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp